Evercore ISI raised the firm’s price target on Iqvia (IQV) to $220 from $180 and keeps an Outperform rating on the shares. The firm says Iqvia is riding high on an improved demand trajectory in pharma and biotech services, with strong Q2 results boosting confidence for 2025 and beyond. The positive momentum is fueled by solid R&DS revenues and better-than-expected TAS performance, particularly in analytics, consulting, and tech, Evercore adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target raised to $225 from $185 at UBS
- Iqvia price target raised to $235 from $209 at Truist
- Iqvia price target raised to $196 from $159 at Baird
- IQVIA Holdings: Balancing Growth in TAS with R&DS Challenges and Economic Pressures Warrants Hold Rating
- IQVIA Holdings: Strong Performance, Growth Potential, and Competitive Advantages Justify Buy Rating and Increased Price Target